ACADIA Pharmaceuticals Q3 EPS $(0.40) Vs $(0.17) Last Year, Sales $211.70M Beat $189.5M Estimate
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals reported Q3 earnings per share (EPS) of $(0.40), which is worse than the $(0.17) EPS from last year. However, the company's sales of $211.70M beat the estimate of $189.5M.
November 02, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ACADIA Pharmaceuticals' Q3 earnings per share (EPS) fell to $(0.40) from $(0.17) last year, but sales of $211.70M exceeded the estimate of $189.5M.
ACADIA Pharmaceuticals' Q3 earnings per share (EPS) fell, indicating a decrease in profitability. However, the company's sales exceeded estimates, which could be seen as a positive sign of growth. The mixed results make the short-term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100